论文部分内容阅读
１９９３年６月至１９９５年６月，用国产促黄体激素释放激素类似物（ＬＨＲＨ－Ａ）或配合炔诺酮治疗１０例难治的子宫内膜异位症。ＬＨＲＨ－Ａ５００μｇ／ｄ肌注，炔诺酮３．１２５ｍｇ／ｄ口服，持续３～６月。所有患者痛经、性交痛、腹泻、阴道流血等症状迅速消失，卵巢巧克力囊肿及阴道壁结节缩小。血清ＩｇＡ水平显著下降。低剂量炔诺酮合并应用对肝、肾功能及血脂成份未见不良影响。ＬＨＲＨ－Ａ治疗后ＩｇＡ水平下降可能与异位内膜活动停止、炎性反应改善有关。ＬＨＲＨ－Ａ联合炔诺酮治疗效果满意且能克服低雌激素状态导致的骨丢失，有临床应用前景。
June 1993 to June 1995, with domestic luteinizing hormone releasing hormone analogues (LHRH-A) or with norethindrone treatment of 10 refractory endometriosis. LHRH-A500μg / d intramuscular, norethisterone 3.125mg / d orally for 3 to 6 months. All patients dysmenorrhea, painful intercourse, diarrhea, vaginal bleeding and other symptoms quickly disappear, ovarian chocolate cyst and vaginal wall nodules reduced. Serum IgA levels decreased significantly. Low-dose norethindrone combined application of liver, kidney function and blood fat composition no adverse effects. The decrease of IgA level after LHRH-A treatment may be related to the cessation of ectopic endometrial activity and the improvement of inflammatory response. LHRH-A combined with norethindrone is effective and can overcome the bone loss caused by low estrogen status, and has clinical application prospect.